A phase II study of pyrazoloacridine in patients with advanced renal cell carcinoma

The aim of this study was to determine the antitumor activity of pyrazoloac ridine in patients with renal cell carcinoma. Eligible patients had advance d renal cell carcinoma with bidimensionally measurable disease, a Karnofsky performance status of at least 70, life expectancy of greater than three m onths, no prior treatment with chemotherapy, and no evidence of brain metas tases. Patients were treated intravenously with 750 mg/m(2) every three wee ks. Twelve patients were enrolled in this study and all were evaluable for response and toxicity. Of the twelve patients, no major responses were achi eved. Toxicity was mild, with three patients requiring a 20% dose reduction . At the dose and schedule used in this trial, pyrazoloacridine is inactive in renal cell carcinoma.